Introduction
============

*Clostridium (Clostridioides) difficile* is an anaerobic, spore forming, Gram-positive bacillus ([@B27]). Historically, *C. difficile* infection (CDI) primarily occurs in hospitalized patients secondary to antibiotic use ([@B22]). However, in the past decade, the proportion of *C. difficile* infection occurring in the community (previously thought to be low risk) is increasing ([@B9]). This highlights the endemicity of *C. difficile* outside healthcare institutions. In addition, the emergence of a more virulent *C. difficile* strain BI/NAP1/027 changed perceptions of *C. difficile* from an easily treated side-effect of antibiotic use to a leading cause of infectious diarrhea with increased morbidity and mortality worldwide ([@B1]; [@B17]; [@B34]).

There are over 800 recognized strain types (ribotypes) of *C. difficile* and only toxin-producing strains are associated with disease ([@B38]; [@B40]). *C. difficile* associated diarrhea is mediated by the production of toxin A (TcdA) and toxin B (TcdB) released into the gut as a result of colonization by toxigenic strains ([@B39]). Early hamster models suggested that TcdA is a key determinant of intestinal inflammation ([@B25]), but subsequent studies suggested that TcdB is more potent ([@B31]; [@B26]). Furthermore, a monoclonal anti-toxin B antibody, but not an anti-toxin A antibody, was effective at reducing recurrence in patients treated for CDI ([@B42]). Also, there is a growing body of evidence for TcdA negative/TcdB positive CDI cases ([@B30]; [@B8]; [@B11]). Therefore, the importance of TcdA in human beings remains uncertain and needs further clarification. Since the emergence of the more virulent BI/NAP1/027 strain of *C. difficile*, the role of a third binary toxin, *C. difficile* transferase (CDT) is increasingly recognized for its association with enhanced virulence and higher patient mortality ([@B15]; [@B5]).

The method used for diagnosing CDI is one of the factors limiting detection of multiple *C. difficile* strains in health or disease. CDI diagnosis is based ideally on detection of free fecal toxin, or, with less specificity, by the presence of toxin genes ([@B35]; [@B27]). Therefore, in the majority of settings, *C. difficile* culture is not performed and so the number of *C. difficile* strains present is not determined.

The likelihood of detecting multi-strain infection or colonization varies with the methods used. Multiple strains can be detected by methods that can distinguish individual strains. In the context of *C. difficile*, these methods include restriction enzyme analysis (REA), pulsed field gel electrophoresis (PGFE), PCR ribotyping, multilocus variable number tandem repeat analysis (MLVA), multilocus sequence typing (MLST), and whole genome sequencing (WGS) ([@B37]; [@B23]; [@B33]). Multiple strains may be detected by the presence of more alleles present at a particular locus than is possible if just one strain is present, dissimilar genotypes from different colonies grown from the same isolate or difference in ability to produce cytotoxin ([@B7]; [@B2]). Notably, the limited studies that have investigated the presence of multiple strains of *C. difficile* in patients with CDI, differ in their case selection criteria and in the methods used for *C. difficile* culture, the number of colonies tested and differentiation of strains (often reflecting the available diagnostic technology) ([Table 1](#T1){ref-type="table"}).

###### 

Summary of studies exploring the presence of dual/mixed strain *Clostridium difficile* infection.

  Author + year   Isolate selection                                                                                                             *C. difficile* identification                                                                                                  Number of cases   Culture method                                                                                          No. of colonies tested per case   *C. difficile* strain differentiation                                                                                   Cases with more than 1 *C. difficile* strain
  --------------- ----------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------ ----------------- ------------------------------------------------------------------------------------------------------- --------------------------------- ----------------------------------------------------------------------------------------------------------------------- ----------------------------------------------
  [@B7]           6 patients with antibiotic associated diarrhea and 1 with diarrhea unrelated to antibiotic use                                *C. difficile* analytical profile index (API). Growth of isolates inhibited by *Clostridium beijerinckii*                      7                 Cycloserine cefoxitin agar.                                                                             At least 10                       Examined for production of cytotoxin using MRC-5 and VERO cells. Identified toxin producing and non-producing strains   7
  [@B32]          4 strains of stored *C. difficile* isolates                                                                                   Unspecified                                                                                                                    3                 Cycloserine cefoxitin fructose agar (CCFA)                                                              8                                 Ethylenediaminetetraacetic acid (EDTA) antigen extraction and immunoblotting                                            2
  [@B10]          110 stored clinical isolates                                                                                                  Unspecified                                                                                                                    110               Cycloserine-cefoxitin-fructose agar with sodium taurocholate (TCCFA).                                   Approximately 10                  Plasmid profile and restriction enzyme analysis (REA)                                                                   0
  [@B29]          10 patients with \>1 isolation of *C. difficile*                                                                              Latex particle agglutination test                                                                                              10                CCFA                                                                                                    10                                REA Examined for production of cytotoxin using VERO cells                                                               0
  [@B41]          Frozen isolates from patients with \>2 *C. difficile* cytotoxin positive fecal samples                                        Colonial morphology, odor and RapID ANA II                                                                                     27                Cycloserine, cefoxitin, egg yolk agar                                                                   1--2                              Random amplified polymorphic DNA (RAPD)                                                                                 0
  [@B39]          Frozen isolates from patients with first episodes of *C. difficile* associated diarrhea                                       Enzyme linked fluorescence assay and culture                                                                                   23                Columbia agar with colistin + nalidixic acid and/or *C. difficile* agar with moxalactam and cysteine.   Approximately 5                   PCR ribotyping, toxinogenicity and clindamycin resistance                                                               2
  [@B36]          Pre-selected from a pool of cases typed as 027 strain                                                                         PCR ribotyping                                                                                                                 39                CCFA                                                                                                    5                                 Multilocus variable number tandem repeat analysis (MLVA)                                                                5
  [@B21]          Patients with 2 episodes of *C. difficile* infection occurring [\>]{.ul}2 weeks apart identified using microbiology records   *C. difficile* neutralization assay and enzyme immunoassay (EIA) for glutamate dehydrogenase (GDH)                             102               Unspecified                                                                                             Unspecified                       PCR ribotyping                                                                                                          0
  [@B20]          Patients with nosocomial *C. difficile* chosen arbitrarily                                                                    Enzyme linked immunosorbent assay (ELISA) for *C. difficile* TcdA and TcdB                                                     11                Cycloserine/cefoxitin agar                                                                              5                                 PCR ribotyping                                                                                                          1
  [@B13]          Paired stool samples from patients collected on the same day                                                                  EIA for GDH and culture                                                                                                        305               Unspecified                                                                                             Unspecified                       Multilocus sequence typing (MLST)                                                                                       21
  [@B4]           Stored isolates from *C. difficile* infected patients                                                                         3 step diagnostic algorithm: (1) EIA for GDH; (2) EIA for *C. difficile* toxin A and/or B; (3) PCR for presence of tcdB gene   102               Pre-reduced, TCCFA                                                                                      95                                PCR ribotyping                                                                                                          16
  [@B34]          Patients with \>1 episode of CDI occuring at least 8 weeks apart                                                              Stool sample positive by PCR for *C. difficile*.                                                                               52                Not specified                                                                                           5                                 MLST                                                                                                                    4
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

Significance
============

A key issue regarding colonization or infection by more than one strain of *C. difficile* is the determination of whether recurrence is due to the same (relapse) or different (reinfection) strain. Most such CDI recurrence studies have examined single or few colonies, or have not used a highly discriminative method, both of which reduce the chance of isolating multiple strains of *C. difficile*. For example, [@B14] examined 90 patients who had recurrent *C. difficile* infection using REA on single *C. difficile* colonies ([@B14]). They showed that 75 participants (83.3%) had a relapse. The remaining 15 (16.7%) participants were found to have a reinfection. Based on the results obtained, there was no evidence to suggest the presence of concomitant carriage of more than 1 strain of *C. difficile* ([@B14]) Although REA has respectable discriminatory power, newer methods such as capillary PCR ribotyping and MLVA are more discriminatory and therefore have a higher chance of identifying mixed *C. difficile* strain infections ([@B24]). [@B21] used PCR ribotyping to explore patients with recurrent *C. difficile* infection. The results suggested that the majority of patients with recurrent *C. difficile* infection within 8 weeks (85/102 patients) had a relapse and not a reinfection. This method has similar discriminative power to REA ([@B24]). Based on the results, there was no evidence to suggest the presence of more than 1 strain of *C. difficile* at any one time ([@B21]). This may be due to the small number of colonies studied as per the published protocol ([@B6]). A recent study by [@B4] recognized this limitation and analyzed approximately 95 colonies per sample and found evidence of more than 1 *C. difficile* ribotype in 16/102 (16%) cases. Even with the large number of colonies studied, there is a chance that less abundant ribotypes will be overlooked ([@B4]).

As *C. difficile* is ubiquitous in nature, the presence of multiple strains could simply reflect a recently ingested strain when another has already colonized or been newly ingested. However, colonization by multiple strains could affect the level of host protection against *C. difficile* infection. At present, there is insufficient evidence to determine the full implications of colonization/infection with more than 1 strain of *C. difficile*. [@B1] demonstrated using an *in vitro* gut model that 2 different population of *C. difficile* (differentiated by antimicrobial susceptibility) were able to concurrently colonize, populate and produce toxin. It is however, not possible to determine the degree of contribution toward toxin production ([@B1]). Longitudinal studies are needed to determine the significance of this phenomenon in human beings.

Data from murine models suggest that colonization with a non-toxigenic strain of *C. difficile* protects against disease in hamster following a challenge with a toxigenic strain ([@B28]). Balmer et al. suggests that in human beings, infection with more than 1 strain of *C. difficile* is likely to be a significant clinical and immunological phenomenon as it may overwhelm the immune system by influencing the host immune response in different ways. This may also affect pathogen evolution, potentiate competitive, or mutualistic pathogen-pathogen interaction, horizontal gene flow and treatment options compared with single strain infection ([@B2]). On the other hand, the presence of two competing strains can be beneficial to the host as they could control each other, similar to how probiotics have been proposed for the prevention of CDI ([@B18]). Notably, Gerding et al. demonstrated that patients with an episode of primary CDI or first recurrence within 8 weeks of the primary episode benefitted from colonization with non-toxigenic *C. difficile* strain M3 (NTCD-M3). The recurrence rate of CDI in patients colonized with NTCD-M3 was significantly lower compared with patients who were not (11 vs. 30%). This reaffirms the notion that colonization with a non-toxigenic strain is beneficial to the host ([@B16]).

Dual Strain Infection
=====================

The observed incidence of mixed *C difficile* toxigenic strain infection has been relatively stable over recent decades at approximately 7--16% of all cases ([@B13], [@B12]; [@B4]; [@B34]). Evidence of mixed strain infection was first reported by [@B7]. The authors found that stool samples from all 6 studied cases showed isolates of *C. difficile* that differed in cytotoxin production ([@B7]). [@B29] later reported a patient who had suffered both a reinfection and relapse. The isolated strain did not produce cytotoxin *in vitro* but toxin was detected in the stools. They hypothesized that this is due to the presence of concomitant strains of *C. difficile.* However, further investigation on 10 different colonies from each sample using REA and cytotoxin studies did not support this ([@B29]). Similarly, in a larger study, [@B41] retrospectively analyzed *C. difficile* colonies using random amplification of polymorphic DNA (RAPD) fingerprinting, but did not identify show more than one *C. difficile* strain per sample time point ([@B41]). This may be due to the fact that mixed infection is a rare occurrence or due to the limitations of the detection methods ([@B3]; [@B4]). More recently, [@B20]; [@B39] investigated 5 or fewer colonies from each sample and found that 1/11 (9.1%) and 2/23 (8.7%) of samples, respectively, had multiple strains of *C. difficile*.

With advancing technology, improved sampling methods and sophisticated genotyping, *C. difficile* transmissions leading to mixed infection and the presence of different toxigenic *C. difficile* strains are being more readily identified ([@B13], [@B12]). However, the reported rate of mixed infection remains similar.

Conclusion
==========

Knowledge and understanding of *C. difficile* has grown considerably since George and colleagues made the link between *C. difficile* and human diseases ([@B19]). Evidence of dual strain infection was first identified by [@B7] after observing differential expression of toxins ([@B7]). With advancing technology, *C. difficile* typing methods are becoming more discriminative and therefore mixed strain infection can be detected more readily. Interestingly, the incidence of mixed strain *C. difficile* infection has been stable.

Currently, there are no studies examining the role of mixed or dual strain infection with *C. difficile* in human beings. A previous study in hamsters suggests that mixed strain infection has the potential to be both beneficial and harmful depending on the nature of the infecting strains ([@B28]). In human beings, it is recognized that patients who are colonized by non-toxigenic *C. difficile* strain is at lower risk of developing *C. difficile* infection while in hospital. This is supported by results from a Phase 2 randomized controlled trial using non-toxigenic *C. difficile* spores to prevent recurrent *C. difficile* infection ([@B16]). Further studies to elucidate the interaction between co-infecting or colonizing and infecting *C. difficile* strains may help identify potential exploitable mechanisms to prevent *C. difficile* infection.
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